All posts

VersaPay upgraded to a buy at Haywood

VersaPay CEO Craig O’Neill.
It’s the rare combination of a target price drop and a rating upgrade, but Haywood analyst Pardeep Sangha says continued pressure on VersaPay’s (VersaPay Stock Quote, Chart TSXV:VPY) stock has moved it into “Buy” territory.

In a research update to clients today, Sangha lowered his one-year price target on VPY from $2.30 to $2.00, while simultaneously upgrading his rating from “Hold” to “Buy”.

The analyst explained his reasoning.

“We are reducing our target price from $2.30 to $2.00 after accounting for dilution from the recently closed financing, but we are upgrading our rating from HOLD to BUY as the current share price provides a good entry point for investors.”

On October 18, VersaPay closed a $9.2-million bought deal financing that was led by Raymond James.

Sangha thinks VersaPay will generate Adjusted EBITDA of negative $11.9-million on revenue of $5.3-million in 018. He expects those numbers will improve to EBITDA of negative $7.1-million on a topline of $12.7-million the following year.

“VersaPay’s shares are down 50% from 2018 highs of $2.70 achieved at the end of May,” Sangha adds. “VersaPay’s shares have fallen due to slower than expected customer roll-outs, the dilution from the recent financing and a broader market sell-off. VersaPay’s customer roll-outs have been slower than expected as the RBC channel has only produced a handful of customers and Livingston has done a limited roll-out thus far. VersaPay currently has over 130,000 end customers and is potentially at risk of missing its target for 250,000 customers at the end of 2018.”

Sangha’s new price target represented a return of 47 per cent at the time of publication.

Tagged with: vpy
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Cannara Biotech is a buy, Research Capital says

Research Capital analyst Greg McLeish said in a July 29 update that Cannara Biotech (Cannara Biotech Stock Quote, Chart, News,… [Read More]

5 hours ago

Ahead of Q2 results, is Tantalus Systems a buy?

Beacon Securities analyst Gabriel Leung noted in a July 30 report that Tantalus Systems (Tantalus Systems Holding Stock Quote, Chart,… [Read More]

5 hours ago

Sanuwave Health is a buy, Roth Capital says

Roth Capital Markets is initiating coverage of Sanuwave Health (Sanuwave Health Stock Quote, Chart, News, Analysts, Financials NASDAQ:SNWV) with a… [Read More]

5 hours ago

Shoulder Innovations is an IPO to watch, this analyst says

Roth Capital Markets analyst Jason Wittes noted in a July 28 pre-IPO report that Shoulder Innovations, a new entrant in… [Read More]

5 hours ago

Nextracker wins price target raise at Roth

Roth Capital Markets analyst Philip Shen said in a July 28 earnings preview that Nextracker (Nextracker Stock Quote, Chart, News,… [Read More]

6 hours ago

Telus is my top telecom stock, Brian Madden says

Brian Madden, Chief Investment Officer at First Avenue Investment Counsel, said on BNN Bloomberg’s Market Call on July 25 that… [Read More]

1 day ago